Value in HealthPub Date : 2026-11-13DOI: 10.1016/j.jval.2026.10.015
Costase Ndayishimiye, Hendrik Koffijberg, Janneke P C Grutters
{"title":"Integrating Organisational and Workforce Outcomes into Health Economic Models: A Scoping Review of Methods.","authors":"Costase Ndayishimiye, Hendrik Koffijberg, Janneke P C Grutters","doi":"10.1016/j.jval.2026.10.015","DOIUrl":"https://doi.org/10.1016/j.jval.2026.10.015","url":null,"abstract":"<p><strong>Objectives: </strong>To map and characterise methods for integrating organisational and workforce outcomes into health economic models and identify related methodological challenges.</p><p><strong>Methods: </strong>A scoping review followed Joanna Briggs Institute (JBI) methodology and PRISMA-ScR guidance. Five databases and grey literature were searched. Eligible studies quantitatively incorporated organisational and/or workforce outcomes into health economic models.</p><p><strong>Results: </strong>Of 1,240 records screened, seven studies were included: five used discrete event simulation (DES) and two used modified Markov models. DES models represented organisational outcomes-such as care processes, patient pathways, capacity constraints, and queueing-structurally, allowing them to emerge endogenously. Markov-based models relied mainly on parameter-based integration, using fixed pathways, predefined states, and imposed delays. Workforce outcomes, such as workload and staffing requirements measured in FTEs, were included in only two studies and were not structurally represented. The stage at which organisational and/or workforce outcomes were integrated differed by modelling approach: DES models incorporated organisational features early during model conceptualisation/design, with further specification during parameterisation, whereas modified Markov models relied more on parameterisation and post-model derivation, particularly for workforce outcomes derived from model outputs. Methodological or data-related challenges were reported in only three studies.</p><p><strong>Conclusions: </strong>Explicit integration of organisational and workforce outcomes in applied health economic models remains uncommon, particularly for workforce outcomes. Organisational outcomes were represented structurally and through model parameters, with DES predominating among the included applications. However, the limited evidence constrains broader methodological conclusions and highlights priorities for further research on workforce integration, model structures, methodological guidance, and data requirements.</p>","PeriodicalId":23508,"journal":{"name":"Value in Health","volume":" ","pages":""},"PeriodicalIF":6.2,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149411130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Value in HealthPub Date : 2026-11-13DOI: 10.1016/j.jval.2026.10.013
Marcus Sellars, Elisabeth Huynh, Rakhee Raghunandan, Martin Howell, Pam Wong, Anna Denejkina, Joanna Coast
{"title":"Assessing the feasibility of discrete choice experiment and best-worst scaling tasks in children and young people of different ages: a think-aloud study using PedsQL.","authors":"Marcus Sellars, Elisabeth Huynh, Rakhee Raghunandan, Martin Howell, Pam Wong, Anna Denejkina, Joanna Coast","doi":"10.1016/j.jval.2026.10.013","DOIUrl":"https://doi.org/10.1016/j.jval.2026.10.013","url":null,"abstract":"<p><strong>Objectives: </strong>To examine age-related patterns in the performance of children and young people (CYP) on discrete choice experiment (DCE) and best-worst scaling (BWS) valuation tasks, and to describe the errors and difficulties encountered.</p><p><strong>Methods: </strong>A think-aloud study was conducted with 40 CYP aged 9-12 years, recruited sequentially beginning with older age groups. Participants completed four BWS and four DCE tasks comprising attributes from the Pediatric Quality of Life Inventory (PedsQL). Interviews were transcribed and coded independently by three raters for comprehension, judgment, and response errors and struggles.</p><p><strong>Results: </strong>A total of 88 errors and struggles were identified: 23 in BWS tasks and 65 in DCE tasks. Task-related DCE error rates were 39.3%, 42.5%, 28.2% and 5.0% among 9-, 10-, 11- and 12-year-olds, respectively; task-related BWS errors occurred only among 9-year olds. Participants who completed BWS tasks first made fewer errors on subsequent DCE tasks (9.9% versus 52.4%). Interviewer prompting was more frequent during DCE tasks (41.0%) than BWS tasks (22.5%). A subset of errors reflected PedsQL item-level interpretive divergence rather than task structure.</p><p><strong>Conclusions: </strong>Younger CYP generally experienced greater task-related difficulty, particularly on DCE tasks, while the BWS tasks tested generated fewer errors and required less prompting. These findings provide provisional information for designing and piloting preference elicitation studies involving CYP in HTA.</p>","PeriodicalId":23508,"journal":{"name":"Value in Health","volume":" ","pages":""},"PeriodicalIF":6.2,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149411127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Value in HealthPub Date : 2026-11-13DOI: 10.1016/j.jval.2026.10.014
Stephen Duffield, Leonardo Koeser, Sjoerd Beentjes, Ava Khamseh
{"title":"Does Health Technology Assessment and Regulatory Real-World Evidence Guidance Support Advanced Causal Analytics? A Policy Review.","authors":"Stephen Duffield, Leonardo Koeser, Sjoerd Beentjes, Ava Khamseh","doi":"10.1016/j.jval.2026.10.014","DOIUrl":"https://doi.org/10.1016/j.jval.2026.10.014","url":null,"abstract":"<p><strong>Background: </strong>Health care decision making bodies such as regulators and health technology assessment (HTA) agencies have increasingly issued guidance on the use of real-world evidence (RWE). However, it is unclear if current guidance supports the use of 'advanced' causal analytics, characterised here by explicit causal estimands, and flexible assumption-lean modelling (for example, doubly robust approaches and nonparametric methods). Correct application of statistical estimators can help developers avoid statistical model mis-specification bias while achieving greater precision.</p><p><strong>Methods: </strong>We undertook a focused review of publicly available RWE guidance and frameworks from international HTA and regulatory bodies, that included recommendations on causal inference, considering (1) articulation of causal questions and estimands; (2) clear separation of identification assumptions from estimation choices; (3) recommendations to support selection of estimation approaches; (4) expectations for diagnostic checks; and (5) whether and how available causal frameworks are used to organise guidance.</p><p><strong>Results: </strong>Guidance primarily emphasises methods to account for confounding bias with limited direction on more granular elements around estimator selection. For example, there is uneven treatment of doubly robust estimation methods which may be endorsed in principle, yet often without sufficient discussion of approaches and practical diagnostics. Causal frameworks are mostly referenced but rarely used to structure guidance, which may have more focus on procedural or reporting elements. Estimand frameworks were frequently referenced in guidance.</p><p><strong>Conclusions: </strong>Strengthening guidance may encourage the application of advanced causal analytics. However, challenges related to the implementation and transparency of these approaches will require upskilling efforts, practical checklists and explainable analytical pipelines.</p>","PeriodicalId":23508,"journal":{"name":"Value in Health","volume":" ","pages":""},"PeriodicalIF":6.2,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149411129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Value in HealthPub Date : 2026-11-12DOI: 10.1016/j.jval.2026.10.012
Fortune B Effiong, Dimeji A Olawuyi, Benjamin B Effiong, Anuoluwapo V Adeyemi, Emmanuel Ekpor, Roseline D Dine, Kenneth O Inaku
{"title":"Cost-Effectiveness of Cabotegravir Long-Acting HIV Pre-Exposure Prophylaxis (PrEP): A Systematic Review of Modelling Studies.","authors":"Fortune B Effiong, Dimeji A Olawuyi, Benjamin B Effiong, Anuoluwapo V Adeyemi, Emmanuel Ekpor, Roseline D Dine, Kenneth O Inaku","doi":"10.1016/j.jval.2026.10.012","DOIUrl":"https://doi.org/10.1016/j.jval.2026.10.012","url":null,"abstract":"<p><strong>Objectives: </strong>Cabotegravir long-acting injectable (CAB-LA) is a promising non-oral pre-exposure prophylaxis (PrEP) for HIV prevention, especially where daily oral adherence is poor. Despite superior efficacy, CAB-LA's high price raises concerns about economic value and implementation across settings. This study reviewed modelling studies on CAB-LA's cost-effectiveness as PrEP across diverse populations and settings.</p><p><strong>Methods: </strong>We searched PubMed, Scopus, Web of Science, Embase and Cochrane Library (2015-2025), assessing CAB-LA's cost-effectiveness versus oral PrEP or no PrEP. Eligible studies reported incremental cost-effectiveness ratios, cost per HIV infection averted, or cost per quality-adjusted life year (QALY) or disability-adjusted life year gained. Reporting quality was assessed using the CHEERS 2022 checklist. Results were narratively synthesized due to heterogeneity.</p><p><strong>Results: </strong>Eleven modelling studies across sub-Saharan Africa, the United States, and Asia-Pacific showed that CAB-LA averted more HIV infections than oral PrEP, especially in high-incidence, low-adherence populations. In high-risk U.S. populations, CAB-LA averted about 71,000 infections and gained 4.65 million QALYs. In Africa, CAB-LA became economically favourable under lower acquisition-cost assumptions, although cost-effective prices varied across models, populations, price years and thresholds. U.S. and Asia-Pacific models found CAB-LA not cost-effective at current prices, requiring 24-88% price reductions. Sensitivity and scenario analyses showed that cost-effectiveness estimates were responsive to CAB-LA price, HIV incidence, ART coverage, adherence, persistence, and programme-delivery assumptions.</p><p><strong>Conclusion: </strong>CAB-LA cost-effectiveness is context dependent and generally more favourable at lower prices, higher-incidence populations, and poor oral PrEP adherence. Wider adoption may require strategies to improve economic value, equitable access, and implementation, especially in resource-constrained settings.</p>","PeriodicalId":23508,"journal":{"name":"Value in Health","volume":" ","pages":""},"PeriodicalIF":6.2,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149411128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Value in HealthPub Date : 2026-11-11DOI: 10.1016/j.jval.2026.10.011
Ilke Akpinar, Jeff Round, Mike Paulden
{"title":"Author Reply.","authors":"Ilke Akpinar, Jeff Round, Mike Paulden","doi":"10.1016/j.jval.2026.10.011","DOIUrl":"https://doi.org/10.1016/j.jval.2026.10.011","url":null,"abstract":"","PeriodicalId":23508,"journal":{"name":"Value in Health","volume":" ","pages":""},"PeriodicalIF":6.2,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149395368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Value in HealthPub Date : 2026-11-11DOI: 10.1016/j.jval.2026.08.017
Eduardo Infante de Oliveira, Joana Alves
{"title":"Beyond the Checklist: Lifecycle Decision Relevance in Medical Device Economic Evaluation.","authors":"Eduardo Infante de Oliveira, Joana Alves","doi":"10.1016/j.jval.2026.08.017","DOIUrl":"https://doi.org/10.1016/j.jval.2026.08.017","url":null,"abstract":"","PeriodicalId":23508,"journal":{"name":"Value in Health","volume":" ","pages":""},"PeriodicalIF":6.2,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149395370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Value in HealthPub Date : 2026-11-10DOI: 10.1016/j.jval.2026.10.010
Louise Hartley, Barbara Johnson, Deborah Profant, Gediwon Milky, Craig Meyer, Amiee Kang, Lixia Yao, Phani Veeranki
{"title":"Assessment of Real-World Data Elements Describing Social Determinants of Health in Outcomes Research in the United States: An ISPOR Special Interest Group Report.","authors":"Louise Hartley, Barbara Johnson, Deborah Profant, Gediwon Milky, Craig Meyer, Amiee Kang, Lixia Yao, Phani Veeranki","doi":"10.1016/j.jval.2026.10.010","DOIUrl":"https://doi.org/10.1016/j.jval.2026.10.010","url":null,"abstract":"<p><strong>Objective: </strong>To identify social determinants of health (SDoH) used in real-world data (RWD) studies in the United States and characterize the frequency of SDoH elements in RWD in the US.</p><p><strong>Methods: </strong>A targeted literature review guided by the National Institute on Minority Health and Health Disparities (NIMHD) Research Framework was conducted. Studies published between 01/01/2022-12/31/2023 were identified from multiple bibliographic databases. Articles meeting inclusion/exclusion criteria were screened independently by two reviewers. Discrepancies were resolved by a third reviewer. Data extraction summarized individual-level SDoH elements across sociocultural, behavioral, physical/built environment, and healthcare systems.</p><p><strong>Results: </strong>Among 43 studies included, 26 (60%) used survey data, 6 (14%) used multiple sources, 4 (9.3%) registries, 2 (4.7%) electronic-health records, 1 (2.3%) administrative claims, and 4 (9.3%) other. Demographics including age (86%), race (91%), sex (93%) and social economic status (SES) (98%) were frequently reported, while ethnic origin, immigration status and gender identity were underreported with over 80% of studies not including these data. Housing status and environment were absent in 91% and 67% of the included studies. Behavioral factors (tobacco, alcohol, drug use) were omitted in 77-88% of selected articles. Health insurance status was reported in half (49%) of the included studies, whereas type of insurance was absent in 67% of the included studies.</p><p><strong>Conclusion: </strong>While core demographics are commonly captured in US RWD, critical SDoH domains are frequently missing. Standardized SDoH frameworks and systematic collection across RWD sources are needed to improve completeness and advance health equity research.</p>","PeriodicalId":23508,"journal":{"name":"Value in Health","volume":" ","pages":""},"PeriodicalIF":6.2,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149387811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Value in HealthPub Date : 2026-11-04DOI: 10.1016/j.jval.2026.10.009
Andrew T Fong, Joshua G Jacob, Jennifer L P Protudjer, Melanie Lloyd, Liz Thyer, Peter S Hsu, Lei Si
{"title":"Health Economic Evaluations in Immunotherapy and Biologic Treatments for Peanut Allergy: A Systematic Review.","authors":"Andrew T Fong, Joshua G Jacob, Jennifer L P Protudjer, Melanie Lloyd, Liz Thyer, Peter S Hsu, Lei Si","doi":"10.1016/j.jval.2026.10.009","DOIUrl":"https://doi.org/10.1016/j.jval.2026.10.009","url":null,"abstract":"<p><strong>Background: </strong>The use of immunotherapy and biologics has garnered increased interest as a potential treatment option for managing peanut allergy.</p><p><strong>Objective: </strong>To systematically review cost-effectiveness in immunotherapy and biologics in peanut allergy management.</p><p><strong>Methods: </strong>A literature search was applied to biomedical and health economics databases, including MEDLINE (via Ovid), Embase (via Ovid), PubMed and Cochrane Library, Web of Science, HTA Database, NHS Economic Evaluation Database, EconLit, Scopus, and several grey literature sources. Cost-effectiveness measures including costs, quality-adjusted life years and incremental cost-effectiveness ratios were extracted from the included studies, and the reporting quality of studies was assessed using the CHEERS checklist. Methodology and outcomes of studies were discussed through a narrative synthesis.</p><p><strong>Results: </strong>Eight economic analyses were included. Non-commercial peanut oral immunotherapy was dominant compared to no treatment, while commercially available products and biologics such as omalizumab were generally not cost-effective compared to no treatment. Sensitivity analyses highlighted the impact of health state utility (HSU) and HRQoL on cost-effectiveness. Reporting quality was assessed and described.</p><p><strong>Conclusion: </strong>Current evidence of economic evaluations to date for immunotherapy and biologics in peanut allergy management is limited by the small number of studies in this field, concentration of evidence in peanut allergy only, heterogeneity in model structures and perspective and the major uncertainty related to HSU and HRQoL. Future research should refine utility measurements, consider indirect costs of peanut allergy and integrate patient-centred perspectives and long-term treatment outcomes to better inform policy decisions and resource allocation in the evolving landscape of peanut allergy therapies.</p>","PeriodicalId":23508,"journal":{"name":"Value in Health","volume":" ","pages":""},"PeriodicalIF":6.2,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149335327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Value in HealthPub Date : 2026-11-04DOI: 10.1016/j.jval.2026.10.008
Antje Förster, Alexander Obbarius, Felix Fischer, Annika Döhmen, Milan Kock, Kathrin Rieger, Ulrich Keilholz, Matthias Rose, Christoph Paul Klapproth
{"title":"Responsiveness, Test-Retest Reliability, and Minimal Important Change of QLU-C10D, PROPr, and EQ-5D-5L in Cancer Patients.","authors":"Antje Förster, Alexander Obbarius, Felix Fischer, Annika Döhmen, Milan Kock, Kathrin Rieger, Ulrich Keilholz, Matthias Rose, Christoph Paul Klapproth","doi":"10.1016/j.jval.2026.10.008","DOIUrl":"https://doi.org/10.1016/j.jval.2026.10.008","url":null,"abstract":"<p><strong>Objectives: </strong>Cost-effectiveness analyses typically rely on health state utility (HSU) scores for the calculation of quality-adjusted life years (QALY). As such analyses influence access to treatment, the psychometric properties of the HSU instruments are crucial. Beyond the established EQ-5D-5L, for the relatively new QLU-C10D and PROPr, there is limited empirical evidence on their psychometric properties. Thus, this study aimed to compare their responsiveness, test-retest reliability, and minimal important change.</p><p><strong>Methods: </strong>EQ-5D-5L, QLU-C10D, and PROPr were collected at five timepoints in an observational sample of 390 outpatient cancer patients. Change groups were determined by both retrospective and prospective anchors. Responsiveness was measured by standardized response mean (SRM), standardized effect size (SES), and detection of change by area under the curve (AUC). Test-retest reliability was measured by intraclass correlation coefficients (ICC). We estimated minimal important change (MIC) with a logistic regression analysis.</p><p><strong>Results: </strong>SRM and SES were mostly small to moderate for all instruments. AUC was poor in all instruments, but significantly higher for the QLU-C10D (0.68-0.69) and PROPr (0.68) than EQ-5D-5L (0.62) in prospective change. ICC was significantly higher for PROPr (0.86) than EQ-5D-5L (0.77) in retrospective change. MIC from T0-T1 was similar for all instruments: 0.03-0.05 for improvement and -0.06 to -0.01 for deterioration.</p><p><strong>Conclusions: </strong>The psychometric performance of the QLU-C10D, the PROPr, and EQ-5D-5L was similar. We could not find evidence for preferring one over the other for QALY estimation in cost-effectiveness analyses. Poor discriminatory power between changed and unchanged patients is a major concern.</p>","PeriodicalId":23508,"journal":{"name":"Value in Health","volume":" ","pages":""},"PeriodicalIF":6.2,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149335328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}